CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0666 (clinicaltrials.gov NCT No: NCT00640978)
Title:PHASE II STUDY OF ERLOTINIB AND RAD001 (EVEROLIMUS) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED PANCREATIC CANCER
Principal Investigator:Milind Javle
Treatment Agent:Erlotinib; RAD001
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if the combination of
RAD001 and erlotinib hydrochloride can slow the growth of advanced pancreatic
cancer. The safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Pancreas
Phase of Study:Phase II
Treatment Agents:Erlotinib
RAD001
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Patients will not be hospitalized for this study
Supported By:Novartis
OSI Pharmaceuticals
Return Visit:Each cycle is 28 days. Patients will be required to return on weeks 1 and 2 in
cycle 1, and then once prior to each cycle.
Home Care:Patients will not have home care for this study


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Milind Javle
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults